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BACKGROUND
Intravenous iron is a standard treatment for patients undergoing hemodialysis, but 
comparative data regarding clinically effective regimens are limited.
METHODS
In a multicenter, open-label trial with blinded end-point evaluation, we randomly 
assigned adults undergoing maintenance hemodialysis to receive either high-dose 
iron sucrose, administered intravenously in a proactive fashion (400 mg monthly, 
unless the ferritin concentration was >700 μg per liter or the transferrin saturation 
was ≥40%), or low-dose iron sucrose, administered intravenously in a reactive fash-
ion (0 to 400 mg monthly, with a ferritin concentration of <200 μg per liter or a 
transferrin saturation of <20% being a trigger for iron administration). The primary 
end point was the composite of nonfatal myocardial infarction, nonfatal stroke, hos-
pitalization for heart failure, or death, assessed in a time-to-first-event analysis. 
These end points were also analyzed as recurrent events. Other secondary end points 
included death, infection rate, and dose of an erythropoiesis-stimulating agent. 
Noninferiority of the high-dose group to the low-dose group would be established 
if the upper boundary of the 95% confidence interval for the hazard ratio for the 
primary end point did not cross 1.25.
RESULTS
A total of 2141 patients underwent randomization (1093 patients to the high-dose 
group and 1048 to the low-dose group). The median follow-up was 2.1 years. Patients 
in the high-dose group received a median monthly iron dose of 264 mg (interquartile 
range [25th to 75th percentile], 200 to 336), as compared with 145 mg (interquartile 
range, 100 to 190) in the low-dose group. The median monthly dose of an erythro-
poiesis-stimulating agent was 29,757 IU in the high-dose group and 38,805 IU in the 
low-dose group (median difference, −7539 IU; 95% confidence interval [CI], −9485 
to −5582). A total of 333 patients (30.5%) in the high-dose group had a primary 
end-point event, as compared with 343 (32.7%) in the low-dose group (hazard 
ratio, 0.88; 95% CI, 0.76 to 1.03; P<0.001 for noninferiority). In an analysis that 
used a recurrent-events approach, there were 456 events in the high-dose group 
and 538 in the low-dose group (rate ratio, 0.78; 95% CI, 0.66 to 0.92). The infection 
rate was the same in the two groups.
CONCLUSIONS
Among patients undergoing hemodialysis, a high-dose intravenous iron regimen ad-
ministered proactively was noninferior to a low-dose regimen administered reactively 
and resulted in lower doses of erythropoiesis-stimulating agent being administered. 
(Funded by Kidney Research UK; PIVOTAL EudraCT number, 2013 - 002267 - 25.)
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Patients undergoing maintenance hemodialysis usually have a negative iron balance owing to reduced absorption and 
increased blood loss.1 The intravenous adminis-
tration of iron has become standard care in the 
management of anemia, and large doses are in-
creasingly used to reduce exposure to erythro-
poiesis-stimulating agents2,3 in order to reduce 
costs and mitigate concerns about potential risks, 
particularly because of cardiovascular toxic ef-
fects that have been observed in trials.4-8 How-
ever, intravenous iron therapy may cause harm by 
increasing the risks of infection, oxidative stress, 
vascular calcification, and atherothrombosis.9-13
Rigorous scientific evaluation of the use of 
high doses of iron in patients undergoing hemo-
dialysis has been limited, which has resulted in 
marked variation in its use among individual 
practitioners and across countries.3 We assessed 
first the noninferiority, and then the safety and 
efficacy, of a high-dose regimen of intravenous 
iron administered proactively, as compared with 
a low-dose regimen of intravenous iron adminis-
tered reactively, in patients undergoing hemodi-
alysis in the Proactive IV Iron Therapy in Haemo-
dialysis Patients (PIVOTAL) trial.
Me thods
Trial Design and Oversight
We conducted this prospective, randomized, open-
label, blinded end-point,14 controlled trial at 50 
sites in the United Kingdom. The trial protocol15 
(available with the full text of this article at 
NEJM.org) was approved by the relevant health 
authorities and institutional review boards, and 
all the patients provided written informed con-
sent. An independent data and safety monitor-
ing committee performed regular safety surveil-
lance. Data were entered into an electronic 
case-report form by the investigators (see the 
Supplementary Appendix, available at NEJM.org) 
and were analyzed at the Robertson Centre for 
Biostatistics, University of Glasgow, in the Unit-
ed Kingdom.
This was an academic investigator–led trial. 
The trial was funded by Kidney Research UK, 
which was supported by an unrestricted grant 
from Vifor Fresenius Medical Care Renal Pharma 
(which also provided iron sucrose for the trial, 
free of charge). Vifor Fresenius Medical Care Re-
nal Pharma had no input into the trial design or 
the data collection or analysis. However, the com-
pany was kept abreast of the progress of the 
trial by regular study reports and newsletters. 
No confidentiality agreements regarding the data 
were in place.
The initial draft of the manuscript was writ-
ten by the first author and revised by all the au-
thors. Medical writing assistance was provided by 
a professional medical writer, funded by Kidney 
Research UK (supported by Vifor Fresenius Medi-
cal Care Renal Pharma). The authors had access 
to the final trial results and take responsibility 
for the accuracy and completeness of the data, 
for the fidelity of the trial to the protocol, and for 
the decision to submit the manuscript for publi-
cation.
Participants
Adults with end-stage kidney disease in whom 
maintenance hemodialysis had been initiated no 
more than 12 months before the initial screen-
ing visit, who had a ferritin concentration of less 
than 400 μg per liter and a transferrin saturation 
of less than 30%, and who were receiving an 
erythropoiesis-stimulating agent were eligible to 
participate. Any iron therapy that had been pre-
scribed previously was discontinued at the screen-
ing visit. The full eligibility criteria are provided 
in the protocol.
Randomization, Treatment, and Follow-up
Using a Web-based randomization system, we ran-
domly assigned participants, in a 1:1 ratio, to 
receive a regimen of high-dose intravenous iron 
administered proactively or a regimen of low-dose 
intravenous iron administered reactively; patients 
were then evaluated monthly. Randomization was 
stratified according to vascular access (dialysis 
catheter vs. arteriovenous fistula or graft), diagno-
sis of diabetes (yes vs. no), and duration of hemo-
dialysis treatment (<5 months vs. ≥5 months).
The ferritin concentration and transferrin sat-
uration were measured monthly (usually during 
the first week of the month), and these values 
determined the monthly dose of iron sucrose to 
be administered intravenously during the subse-
quent week of hemodialysis (usually the second 
week of the month). In the high-dose group, 
400 mg of iron sucrose per month, to be admin-
istered intravenously, was prescribed to the pa-
tients, with safety cutoff limits (ferritin concen-
tration of 700 μg per liter or a transferrin 
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saturation of 40%) above which further intrave-
nous iron administration was withheld pending 
repeat testing 1 month later. Patients in the low-
dose group received a monthly dose of 0 mg to 
400 mg of iron sucrose as required to maintain 
a minimum target ferritin concentration of 200 μg 
per liter and a transferrin saturation of 20%, in 
line with accepted clinical guidelines (for details 
of the iron-dosing regimen, see the Supplementary 
Appendix). Iron therapy was temporarily withheld 
if the trial team identified an active infection that 
was deemed by the investigator to be sufficient to 
contraindicate the use of intravenous iron. Ther-
apy was restarted when it was judged by the in-
vestigator to be safe to do so.
Clinicians selected the dose of erythropoiesis-
stimulating agent that would be sufficient to main-
tain a hemoglobin level of 10 to 12 g per deciliter.16 
Apart from the dose of erythropoiesis-stimulating 
agent, the trial teams treated patients according 
to standard practice.
Trial End Points
The primary end point was the composite of non-
fatal myocardial infarction, nonfatal stroke, hos-
pitalization for heart failure, or death from any 
cause, assessed in a time-to-first-event analysis; 
definitions of the end-point events are provided 
in the Supplementary Appendix. The first second-
ary end point consisted of the components of the 
primary end point, including first and repeat 
events, which were analyzed as recurrent events. 
Other secondary efficacy end points included 
death from any cause; the composite of fatal or 
nonfatal myocardial infarction, fatal or nonfatal 
stroke, or hospitalization for heart failure; and 
each of the three subcomponents of that end 
point, all assessed in time-to-first-event analyses. 
An independent committee whose members were 
unaware of the trial-group assignments adjudi-
cated these events according to prespecified crite-
ria. Additional secondary efficacy end points in-
cluded the dose of erythropoiesis-stimulating 
agent, the incidence of blood transfusion, and two 
quality-of-life measures (the European Quality of 
Life–5 Dimensions [EQ-5D] questionnaire and the 
Kidney Disease Quality of Life instrument).
Safety end points included vascular access 
thrombosis, hospitalization for any cause, and 
hospitalization for infection, each assessed in a 
time-to-first-event analysis, and the rate of epi-
sodes of infection. Laboratory tests, including the 
hemoglobin level, serum ferritin concentration, 
and transferrin saturation, were assessed monthly. 
Data on serious adverse events were collected 
prospectively, and events were coded with the 
use of the Medical Dictionary for Regulatory Activities 
(MedDRA), version 15.1. Data on nonserious 
adverse events, other than infection and vascular 
access thrombosis, were not collected.
Statistical Analysis
In the initial sample-size calculations, we as-
sumed a 3-year event rate of 40% in the low-dose 
group and a 10% loss to follow-up (including 
loss to follow-up due to kidney transplantation). 
Thus, we estimated that a sample of 2080 patients 
who had 631 primary end-point events would pro-
vide the trial with 80% power to assess the non-
inferiority of high-dose iron to low-dose iron, with 
a noninferiority limit for the hazard ratio of 1.25.
Summary statistics are provided as numbers 
and percentages, as mean values with standard 
deviations, and as median values with interquar-
tile ranges (25th to 75th percentile). Treatment 
effects were estimated as the effect in the high-
dose group as compared with (or minus) the ef-
fect in the low-dose group, with adjustment for 
the stratification variables at randomization. The 
primary end point was analyzed first in terms of 
noninferiority in the intention-to-treat popula-
tion, which included all the patients who had un-
dergone randomization validly, with a supporting 
analysis in a per-protocol population that excluded 
patients with a major protocol violation. Analyses 
were censored at the date of kidney transplanta-
tion, withdrawal of consent, loss to follow-up, or 
transfer to home or peritoneal dialysis, which-
ever came first. Noninferiority was also assessed 
in a sensitivity analysis that included only patients 
who were currently receiving treatment, with data 
censored after patients discontinued the trial 
drug. The time-to-first-event analyses were con-
ducted with the use of cause-specific Cox pro-
portional-hazards models, including the stratifi-
cation variables and the treatment variable. The 
noninferiority analysis tested the null hypothesis 
that the hazard ratio for the treatment effect was 
at least 1.25 against the alternative that the haz-
ard ratio was less than 1.25, with a required 
one-sided significance level of 0.025. If noninfe-
riority was established, a two-sided superiority 
test (Wald statistic) was carried out with no pen-
alty regarding the P value.
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Characteristic
Proactive, High-Dose Iron Regimen 
(N = 1093)
Reactive, Low-Dose Iron Regimen 
(N = 1048)
Age — yr 62.7±14.9 62.9±15.1
Male sex — no. (%) 710 (65.0) 688 (65.6)
Race — no. (%)†
White 868 (79.4) 830 (79.2)
Black 93 (8.5) 97 (9.3)
Asian 96 (8.8) 89 (8.5)
Other 36 (3.3) 32 (3.1)
Median duration of dialysis treatment (IQR) — mo 4.9 (2.8–8.4) 4.8 (2.8–8.1)
Vascular access — no. (%)
Dialysis catheter 449 (41.1) 428 (40.8)
Arteriovenous fistula or graft 644 (58.9) 620 (59.2)
Cardiovascular disease — no. (%)
Atrial fibrillation 96 (8.8) 68 (6.5)
Heart failure 41 (3.8) 45 (4.3)
Hypertension 804 (73.6) 753 (71.9)
Hyperlipidemia 277 (25.3) 258 (24.6)
Peripheral vascular disease 92 (8.4) 95 (9.1)
Previous myocardial infarction 97 (8.9) 87 (8.3)
Previous stroke 85 (7.8) 91 (8.7)
Diabetes — no. (%) 494 (45.2) 456 (43.5)
Smoking status — no. (%)
Current smoking 145 (13.3) 104 (9.9)
Former smoking 261 (23.9) 284 (27.1)
Never smoked 687 (62.9) 660 (63.0)
Weight — kg 81.3±21.0 82.9±20.9
Body-mass index‡ 28.5±7.1 29.0±6.7
Blood pressure — mm Hg§
Systolic 145±24 145±24
Diastolic 74±14 74±15
Hemoglobin — g/dl 10.6±1.4 10.5±1.4
Median serum ferritin concentration (IQR) — μg/liter 214 (132–305) 217 (137–301)
Median transferrin saturation (IQR) — % 20 (16–24) 20 (16–24)
Median C-reactive protein level (IQR) — mg/liter 6.0 (3.3–13.9) 7.0 (4.0–15.0)
Median dose of erythropoiesis-stimulating agent (IQR) — IU/wk¶ 8000 (5000–10,000) 8000 (5000–12,000)
Primary cause of kidney failure — no. (%)
Diabetic nephropathy 363 (33.4) 349 (33.5)
Glomerular disease 191 (17.6) 203 (19.5)
Hypertension 129 (11.9) 106 (10.2)
Tubulointerstitial disease‖ 113 (10.4) 88 (8.4)
Renovascular disease 64 (5.9) 83 (8.0)
Polycystic kidney disease 62 (5.7) 55 (5.3)
Other 61 (5.6) 68 (6.5)
Unknown 110 (10.1) 96 (9.2)
*  Plus–minus values are means ±SD. There were no significant differences between the two groups except for smoking status (P = 0.03) and the 
hemoglobin level (P = 0.04). Percentages may not total 100 because of rounding. IQR denotes interquartile range (25th to 75th percentile).
†  Race was reported by the patients.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Blood-pressure measurements were taken before hemodialysis.
¶  For darbepoetin alfa and methoxy polyethylene glycol-epoetin beta, the weekly reported dose was multiplied by 200 to convert the units from 
micrograms to international units.
‖  Tubulointerstitial disease included pyelonephritis, reflux nephropathy, and obstructive uropathy.
Table 1. Characteristics of the Patients at Baseline.*
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The incidence of death from any cause and a 
composite of myocardial infarction, stroke, or 
hospitalization for heart failure as recurrent 
events was analyzed with the use of the propor-
tional-means model of Lin et al.17 and described 
in the form of mean frequency functions (meth-
od of Ghosh and Lin).18 Other statistical methods 
and details regarding statistical assumptions are 
described in the Supplementary Appendix. The 
results for the secondary end points are reported 
as point estimates and 95% confidence intervals 
with no adjustment for multiple comparisons, so 
the confidence intervals should not be used to 
infer definitive treatment effects. The cumulative 
doses of intravenous iron were compared between 
the treatment groups with the use of Wilcoxon 
rank-sum tests. The statistical analysis plan is 
available with the protocol at NEJM.org.
R esult s
Patients
The trial was conducted from November 2013 to 
June 2018. Of the 2589 patients who were screened 
for entry into the trial, 448 did not meet the cri-
teria for randomization. A total of 2141 patients 
were randomly assigned to a treatment group 
(1093 patients to the high-dose group and 1048 to 
the low-dose group) and constituted the inten-
tion-to-treat population (Fig. S1 in the Supple-
mentary Appendix). Follow-up continued until 
June 6, 2018.
The characteristics of the patients at baseline 
were generally well balanced between the two 
treatment groups, except for smoking status 
(P = 0.03) and the hemoglobin level (P = 0.04) 
(Table 1). The prevalence of cardiovascular dis-
ease (a history of one or more of the following: 
myocardial infarction, stroke, heart failure, atrial 
fibrillation, or peripheral vascular disease) was 
29.6% in the high-dose group and 28.2% in the 
low-dose group. With the exception of angioten-
sin-converting–enzyme inhibitors or angioten-
sin-receptor blockers and phosphate binders, the 
use of medications at baseline was similar in the 
two groups (Table S1 in the Supplementary Ap-
pendix).
Excluding patients who died or underwent kid-
Figure 1. Iron Administration over Time.
The mean cumulative doses of intravenous iron that were received by the patients in the two treatment groups are 
shown over time. At all the time points after baseline, patients in the group that received high-dose iron proactively 
received greater cumulative doses of iron than did the patients in the group that received low-dose iron reactively 
(P<0.001 for all time points). The cumulative doses of iron were compared between the treatment groups with the 
Wilcoxon rank-sum test. I bars indicate 95% confidence intervals.
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ney transplantation, follow-up was incomplete for 
162 patients (14.8%) in the high-dose group and 
for 175 (16.7%) in the low-dose group (Fig. S1 in 
the Supplementary Appendix). The median fol-
low-up was 2.1 years, with a maximum follow-up 
of 4.4 years.
Doses of Iron and Erythropoiesis-
Stimulating Agents
The cumulative doses of intravenous iron were 
greater in the high-dose group than in the low-
dose group (Fig. 1). At month 12, the patients in 
the high-dose group had received a median of 
2000 mg (95% confidence interval [CI], 1900 to 
2100) more iron than the patients in the low-dose 
group. The median monthly dose of iron was 
264 mg (interquartile range, 200 to 336) in the 
high-dose group and 145 mg (interquartile range, 
100 to 190) in the low-dose group; the median 
difference in the monthly iron dose was 121 mg 
(95% CI, 114 to 129). The ferritin concentrations 
and transferrin saturation both increased from 
baseline rapidly with the high-dose regimen, as 
compared with the low-dose regimen (Figs. S2 
and S3 in the Supplementary Appendix).
The cumulative dose of erythropoiesis-stimu-
lating agent was lower in the high-dose group 
than in the low-dose group at all the postbase-
line time points examined through 36 months 
(Fig. S4 in the Supplementary Appendix). The 
median monthly dose of erythropoiesis-stimu-
lating agent was 19.4% lower in patients receiv-
ing the high-dose regimen (29,757 IU per month; 
interquartile range, 18,673 to 48,833) than in 
patients receiving the low-dose regimen (38,805 IU 
per month; interquartile range, 24,377 to 60,620) 
(median difference, −7539 IU per month; 95% CI, 
−9485 to −5582) (Table 2). Although patients in the 
two treatment groups had increases from base-
line in the hemoglobin level over time, more 
rapid increases were observed in the high-dose 
group than in the low-dose group (Fig. S5 in the 
Supplementary Appendix). Plots of the median 
values and interquartile ranges of the above-men-
tioned laboratory tests are shown in Figures S6 
through S10 in the Supplementary Appendix.
Primary End Point
A primary end-point event occurred in 333 patients 
(30.5%) in the high-dose group, as compared with 
343 (32.7%) in the low-dose group (hazard ratio, 
0.88; 95% CI, 0.76 to 1.03; P<0.001 for noninfe-* 
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riority; P = 0.11 for superiority) (Fig. 2A and Ta-
ble 2). Results were similar in the per-protocol 
population (hazard ratio, 0.88; 95% CI, 0.75 to 
1.02; P<0.001 for noninferiority) and after the 
censoring of data from patients after they dis-
continued the trial drug. The effect of high-
dose iron therapy on the primary end point was 
consistent across all the prespecified subgroups 
(vascular access, diabetes status, and duration 
of dialysis treatment), with no significant inter-
actions observed (Fig. S11 in the Supplementa-
ry Appendix).
Secondary Efficacy End Points
There were 246 deaths (22.5% of the patients) in 
the high-dose group and 269 (25.7%) in the low-
dose group (hazard ratio, 0.84; 95% CI, 0.71 to 
1.00) (Fig. 2B and Table 2), with consistent re-
sults observed across the prespecified subgroups 
(Fig. S11 in the Supplementary Appendix). The 
rates of fatal or nonfatal myocardial infarction, 
fatal or nonfatal stroke, or hospitalization for 
heart failure and the individual components of 
myocardial infarction and stroke were similar in 
the two treatment groups (Table 2). The rate of 
hospitalization for heart failure was lower in the 
high-dose group than in the low-dose group 
(hazard ratio, 0.66; 95% CI, 0.47 to 0.93).
Death and a composite of myocardial infarc-
tion, stroke, or hospitalization for heart failure 
as recurrent events occurred at a rate of 20.6 
events per 100 patient-years in the high-dose 
group, as compared with 26.1 events per 100 
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Figure 2. Cumulative Incidence of the Primary Efficacy 
End Point, of Death from Any Cause, and of Death 
from Any Cause and a Composite of Cardiovascular 
Events as Recurrent Events.
Panel A shows the cumulative event rates for the pri-
mary efficacy end point (a composite of death from 
any cause, nonfatal myocardial infarction, nonfatal 
stroke, and hospitalization for heart failure). Panel B 
shows the rates of death from any cause, and Panel C 
shows the rates of death from any cause and a com-
posite of myocardial infarction, stroke, and hospitaliza-
tion for heart failure as recurrent events plotted in the 
form of mean frequency functions with the use of the 
method of Ghosh and Lin.18 The hazard ratios (with 
95% confidence intervals) and rate ratio (with the 95% 
confidence interval) were adjusted for the baseline 
stratification variables of vascular access, diabetes sta-
tus, and duration of dialysis treatment.
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patient-years in the low-dose group (rate ratio, 
0.78; 95% CI, 0.66 to 0.92) (Fig. 2C and Table 2). 
Patients in the high-dose group were less likely 
to receive blood transfusions than those in the 
low-dose group (hazard ratio, 0.79; 95% CI, 0.65 
to 0.95). There were no significant between-group 
differences with regard to changes from baseline 
in either the EQ-5D quality-of-life health index or 
the Kidney Disease Quality of Life overall score.
Safety
Vascular access thrombosis occurred in 262 pa-
tients (24.0%) in the high-dose group and in 218 
(20.8%) in the low-dose group. The rates of hos-
Event
Proactive, High-Dose 
Iron Regimen 
(N = 1093)
Reactive, Low-Dose 
Iron Regimen 
(N = 1048)
no. of patients with event (%)
Any serious adverse event 709 (64.9) 671 (64.0)
Infection or infestation 341 (31.2) 327 (31.2)
Injury, poisoning, or procedural complication 220 (20.1) 224 (21.4)
Cardiac disorder 154 (14.1) 165 (15.7)
General disorder or administration-site condition 159 (14.5) 129 (12.3)
Respiratory, thoracic, or mediastinal disorder 107 (9.8) 121 (11.5)
Gastrointestinal disorder 111 (10.2) 110 (10.5)
Surgical or medical procedure 117 (10.7) 102 (9.7)
Metabolism or nutrition disorder 95 (8.7) 116 (11.1)
Vascular disorder 90 (8.2) 104 (9.9)
Nervous system disorder 98 (9.0) 82 (7.8)
Renal or urinary disorder 34 (3.1) 48 (4.6)
Investigation† 33 (3.0) 44 (4.2)
Musculoskeletal or connective-tissue disorder 28 (2.6) 37 (3.5)
Neoplasm, benign, malignant, or unspecified, including cysts 
and polyps
27 (2.5) 27 (2.6)
Psychiatric disorder 21 (1.9) 26 (2.5)
Hepatobiliary disorder 23 (2.1) 18 (1.7)
Skin or subcutaneous-tissue disorder 22 (2.0) 14 (1.3)
Blood or lymphatic system disorder 14 (1.3) 17 (1.6)
Reproductive system or breast disorder 2 (0.2) 7 (0.7)
Eye disorder 2 (0.2) 6 (0.6)
Social circumstance‡ 2 (0.2) 3 (0.3)
Immune system disorder 3 (0.3) 0
Congenital, familial, or genetic disorder 1 (0.1) 0
Ear or labyrinth disorder 0 1 (0.1)
Endocrine disorder 1 (0.1) 0
*  Data are the numbers and percentages of patients who had a serious adverse event, according to Medical Dictionary for 
Regulatory Activities, version 15.1, system organ class.
†  Investigation was defined as results of a laboratory test or other medical investigation that met the requirements for a 
serious adverse event.
‡  Social circumstance was defined as an event of medical relevance to the evaluation of other data (e.g., hospitalization 
for social reasons, such as general deterioration in health that led to an inability to function at home).
Table 3. Serious Adverse Events.*
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pitalization for any cause and for infection were 
similar in the two treatment groups (Table 2). The 
rate of all episodes of infection in the high-dose 
group was 63.3 events per 100 patient-years, as 
compared with 69.4 events per 100 patient-years 
in the low-dose group (rate ratio, 0.91; 95% CI, 
0.79 to 1.05).
Serious adverse events occurred in 709 patients 
(64.9%) in the high-dose group and in 671 (64.0%) 
in the low-dose group. The rates of the most com-
mon serious adverse events, analyzed according 
to MedDRA system organ class, were generally 
similar in the two treatment groups (Table 3). 
Infection was the most common noncardiovas-
cular cause of death, and the rates were similar 
in the two treatment groups (Table S2 in the Sup-
plementary Appendix).
Other End Points
High-dose iron administered proactively was as-
sociated with a small decrease in the platelet count 
over time, as compared with a small increase in 
the group that received low-dose iron adminis-
tered reactively (Figs. S12 and S13 in the Supple-
mentary Appendix). No significant between-group 
differences were observed with regard to the se-
rum albumin concentration (Figs. S14 and S15 
in the Supplementary Appendix).
Discussion
In contrast to results from observational stud-
ies,19-24 the results of this trial showed that the 
use of a high-dose intravenous iron regimen 
administered proactively was noninferior to the 
use of a low-dose intravenous iron regimen ad-
ministered reactively and was not associated 
with higher risks of death, major adverse cardio-
vascular events, or infection. Furthermore, pa-
tients who received high-dose iron therapy had 
fewer blood transfusions and received lower dos-
es of erythropoiesis-stimulating agents to main-
tain target hemoglobin levels than those in the 
low-dose group; patients in the high-dose group 
also had a faster increase in the hemoglobin level. 
In addition, high-dose iron administered proac-
tively appeared to protect against recurrent events, 
including hospitalization for heart failure — a 
finding that is consistent with the results of pla-
cebo-controlled trials of intravenous iron therapy 
in patients with heart failure.25-28
The cardiovascular safety profile that is as-
sociated with the use of high-dose intravenous 
iron therapy to maintain a target hemoglobin 
level is notable, given the safety concerns about 
using higher doses of erythropoiesis-stimulating 
agents to elevate the hemoglobin level. We specu-
late that the dose-sparing effect of intravenous 
iron therapy on erythropoiesis-stimulating agents 
might contribute to the cardiovascular safety pro-
file of high-dose iron therapy. It is also possible 
that iron replacement in patients with iron defi-
ciency has direct cardiovascular benefits.
The absence of a greater risk of infection with 
the proactive, high-dose intravenous iron regimen 
is important, given studies that have suggested 
that iron might potentiate bacterial growth and 
infection.12,29-32 In our trial, the investigators were 
advised to discontinue iron therapy in patients 
during episodes of infection.
The most appropriate intravenous iron-re-
placement regimen in adults undergoing dialysis 
is unknown, which has resulted in different lo-
cal, national, and international recommendations 
and practices. Observational studies have raised 
concern that monthly doses of 300 mg or more 
of intravenous iron are associated with poor out-
comes.19-21 In the high-dose group of our trial, we 
used a monthly dose of 400 mg, with a per-pro-
tocol temporary discontinuation of treatment only 
if the ferritin concentration exceeded 700 μg per 
liter or the transferrin saturation was 40% or 
higher. Patients in the high-dose group received 
approximately twice the amount of iron as those 
in the low-dose group over the first year of the 
trial and 83.5% more iron per month over the 
course of the trial. The median monthly dose of 
iron that was administered in the high-dose group 
was 264 mg, which is greater than the approxi-
mately 218-mg dose that was reported by the Di-
alysis Outcomes and Practice Patterns Study in the 
United States.33 Given the absence of harm that 
was observed with the high-dose intravenous iron 
regimen in our trial, the safety and efficacy of 
even higher doses of iron might be explored in 
further trials.
The strengths of our trial include its size and 
long duration of follow-up, the collection and adju-
dication of important clinical events, and the lim-
ited exclusion criteria that allowed for the enroll-
ment of a cohort of patients representative of 
those seen in routine clinical practice. Limitations 
of the trial include the restriction of the trial sites 
to a single country. Thus, the generalizability of 
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the trial findings to dialysis populations world-
wide is unclear. The open-label nature of the trial 
may have potentially biased the rates of blood 
transfusion. Ongoing iron losses that have been 
associated with hemodialysis, combined with 
the iron-storage capacity of the reticuloendo-
thelial system and the withholding of iron in 
patients with markedly elevated iron indexes 
(ferritin concentration of >700 μg per liter or 
transferrin saturation of ≥40%), were expected 
to reduce the risk of overt toxic effects of iron in 
this population.1 However, the safety of this 
high-dose iron regimen cannot be confirmed 
beyond the duration of the current trial. Finally, 
because quality-of-life data were missing for 
many patients, the interpretation of the effect of 
the iron dose with regard to these end points is 
limited.
In conclusion, this trial showed that, among 
patients undergoing hemodialysis, the use of a 
high-dose regimen of intravenous iron adminis-
tered proactively resulted in a significantly lower 
dose of erythropoiesis-stimulating agent and a 
lower incidence of blood transfusion than the use 
of a low-dose regimen administered reactively. 
Mortality and the incidence of nonfatal cardio-
vascular events and infections did not differ sig-
nificantly between the two treatment groups.
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